MSB Stock Overview
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mesoblast Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$2.42 |
| 52 Week High | AU$3.09 |
| 52 Week Low | AU$0.26 |
| Beta | 2.31 |
| 1 Month Change | 53.65% |
| 3 Month Change | 133.82% |
| 1 Year Change | 706.67% |
| 3 Year Change | 74.10% |
| 5 Year Change | 15.24% |
| Change since IPO | 202.50% |
Recent News & Updates
Shareholder Returns
| MSB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 31.5% | 0.1% | -2.7% |
| 1Y | 706.7% | 3.1% | 6.5% |
Return vs Industry: MSB exceeded the Australian Biotechs industry which returned 3.1% over the past year.
Return vs Market: MSB exceeded the Australian Market which returned 6.5% over the past year.
Price Volatility
| MSB volatility | |
|---|---|
| MSB Average Weekly Movement | 19.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: MSB's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: MSB's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 73 | Silviu Itescu | www.mesoblast.com |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.
Mesoblast Limited Fundamentals Summary
| MSB fundamental statistics | |
|---|---|
| Market cap | AU$2.76b |
| Earnings (TTM) | -AU$141.26m |
| Revenue (TTM) | AU$9.48m |
291.4x
P/S Ratio-19.6x
P/E RatioIs MSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSB income statement (TTM) | |
|---|---|
| Revenue | US$5.90m |
| Cost of Revenue | US$41.07m |
| Gross Profit | -US$35.17m |
| Other Expenses | US$52.79m |
| Earnings | -US$87.96m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.077 |
| Gross Margin | -595.87% |
| Net Profit Margin | -1,490.27% |
| Debt/Equity Ratio | 23.8% |
How did MSB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 04:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mesoblast Limited is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Russell Wright | Barclay Pearce Capital Pty Limited |
| Stuart Roberts | Bell Potter |